Evaluating the impact of population-based and cohort-based models in cost-effectiveness analysis: a case study of pneumococcal conjugate vaccines in infants in Germany
This analysis highlights the importance of accurately identifying the relevant population when conducting CEAs of vaccines. This is particularly crucial when a vaccine produces indirect effects in individuals who are not directly vaccinated, as this otherwise leads to an underestimation of cost-effectiveness.
Authors
- Johnna Perdrizet (ORCID: https://orcid.org/0000-0002-4260-7607)
- Christian Theilacker (ORCID: https://orcid.org/0000-0003-0821-9202)
- Julia Schiffner-Rohe
- Dominik Schröder (ORCID: https://orcid.org/0000-0002-3564-4725)
- An Ta (ORCID: https://orcid.org/0000-0003-0929-6365)
- Maren Laurenz
- Felicitas Kühne (ORCID: https://orcid.org/0000-0001-9762-3842)
- Christof von Eiff (ORCID: https://orcid.org/0000-0002-7821-2359)
- Aleksandar Ilic
Institutions
- Pfizer (United Kingdom) (GB)
- Pfizer (Germany) (DE)
- Evidence (Italy) (IT)
- Pfizer (Canada) (CA)
- Cytel (United States) (US)
Publication Details
- Journal
- Journal of Medical Economics
- Published
- 2025-07-21
- DOI
- https://doi.org/10.1080/13696998.2025.2536430
- Primary Topic
- Pharmaceutical studies and practices
- Type
- article
- Field-Weighted Citation Impact
- 0.00